Biogen's US Tecfidera Sales Could Plunge By $2.8bn In 2021
Market Reacts To Mylan ‘At-Risk’ Launch
Executive Summary
Mylan’s “at-risk” launch of a generic version of Biogen’s Tecfidera could cost the originator dear as generic competition to the one of the most lucrative small-molecule opportunities arrives in the US.